The NEFIGAN Trial is a clinical study evaluating the safety and effectiveness of the drug, NEFECON, in patients with IgA nephropathy. The study is sponsored by Pharmalink AB.
IgA nephropathy is a chronic kidney disease that progresses to renal failure in 20-40% of diagnosed patients. Disease progression is most often slow, taking 5 to 30 years before dialysis or kidney transplantation is required. Despite the long progression time, there is a lack of treatments that can effectively halt the gradual decline in renal function in IgA nephropathy patients.
NEFECON is an oral drug under development specifically designed for the safe and effective treatment of patients with IgA nephropathy at risk of renal failure.
A Phase 2a exploratory clinical trial has been conducted with promising efficacy and safety results.
A larger Phase 2b clinical trial, the NEFIGAN Trial, is on-going in 50-60 renal centres in 10 European countries, evaluating the efficacy and safety of two different doses of NEFECON in the treatment of patients with primary IgA nephropathy at risk of developing end-stage renal disease.